BR0112475A - N-óxidos como pró-drogas antagonistas de receptor de nk1 de derivados 4-fenil-piridina - Google Patents

N-óxidos como pró-drogas antagonistas de receptor de nk1 de derivados 4-fenil-piridina

Info

Publication number
BR0112475A
BR0112475A BR0112475-7A BR0112475A BR0112475A BR 0112475 A BR0112475 A BR 0112475A BR 0112475 A BR0112475 A BR 0112475A BR 0112475 A BR0112475 A BR 0112475A
Authority
BR
Brazil
Prior art keywords
lower alkyl
hydrogen
oxides
receptor antagonist
independently
Prior art date
Application number
BR0112475-7A
Other languages
English (en)
Other versions
BR0112475B1 (pt
BRPI0112475B8 (pt
Inventor
Torsten Hoffmann
Sonia Maria Poli
Patrick Schnider
Andrew Sleight
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR0112475A publication Critical patent/BR0112475A/pt
Publication of BR0112475B1 publication Critical patent/BR0112475B1/pt
Publication of BRPI0112475B8 publication Critical patent/BRPI0112475B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

"N-óXIDOS COMO PRó-DROGAS ANTAGONISTAS DE RECEPTOR DE NK1 DE DERIVADOS 4-FENIL-PIRIDINA". A invenção refere-se a compostos da fórmula (I) em que R é hidrogênio, alquila inferior, alcóxi inferior ou trifluorometila; R^ 1^ é hidrogênio ou halogênio; ou R e R^ 1^ podem ser juntos com os átomos de carbono no anel ao qual eles estão ligados -CH=CH-CH=CH-; R^ 2^ e R^ 2'^ são independentemente um do outro hidrogênio, halogênio, trifluorometila, alcóxi inferior ou ciano; ou R^ 2^ e R^ 2'^ podem ser juntos -CH=CH-CH=CH-, opcionalmente substituídos por um ou dois substituintes selecionados de alquila inferior ou alcóxi inferior; R^ 3^, R^ 3'^ são independentemente um do outro hidrogênio, alquila inferior ou cicloalquila; R^ 4^, R^ 4'^ são independentemente um do outro -(CH~ 2~)~ m~OR^ 6^ ou alquila inferior; ou R^ 4^ e R^ 4'^ formam juntos com o átomo de N ao qual eles estão ligados a uma amina cíclica terciária do grupo (II); R^ 5^ é hidrogênio, hidróxi, alquila inferior, -alcóxi inferior, -(CH~ 2~)~ m~OH, -COOR^ 3^, -CON(R^ 3^)~ 2~, -N(R~ 3~)CO-alquila inferior ou -C(O)R^ 3^; R^ 6^ é hidrogênio, alquila inferior ou fenila; X é -C(O)N(R^ 6^)-,-N(R^ 6^)C(O)-; -(CH~ 2~)~ m~O- ou -O(CH~ 2~)~ m~; n é 0, 1, 2, 3 ou 4; e m é 1, 2 ou 3; e a seus sais de adição ácidos farmaceuticamente aceitáveis. Foi constatado que esses compostos podem ser usados como pró-drogas para o tratamento ou prevenção de doenças relacionadas ao receptor de NK1.
BRPI0112475A 2000-07-14 2001-07-09 n-óxido de derivados 4-fenil-piridina como antagonista de receptor nk1, seu medicamento, seu processo de preparação e seus usos BRPI0112475B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00115287 2000-07-14
PCT/EP2001/007850 WO2002006236A1 (en) 2000-07-14 2001-07-09 N-oxides as nk1 receptor antagonist prodrugs of 4-phenyl-pyridine derivatives

Publications (3)

Publication Number Publication Date
BR0112475A true BR0112475A (pt) 2003-07-29
BR0112475B1 BR0112475B1 (pt) 2013-10-15
BRPI0112475B8 BRPI0112475B8 (pt) 2021-05-25

Family

ID=8169262

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0112475A BRPI0112475B8 (pt) 2000-07-14 2001-07-09 n-óxido de derivados 4-fenil-piridina como antagonista de receptor nk1, seu medicamento, seu processo de preparação e seus usos

Country Status (39)

Country Link
US (4) US6593472B2 (pt)
EP (1) EP1303490B1 (pt)
JP (1) JP3950044B2 (pt)
KR (1) KR100501608B1 (pt)
CN (1) CN1178917C (pt)
AR (1) AR029717A1 (pt)
AT (1) ATE400556T1 (pt)
AU (1) AU7061901A (pt)
BR (1) BRPI0112475B8 (pt)
CA (1) CA2415890C (pt)
CY (1) CY1108557T1 (pt)
CZ (1) CZ303639B6 (pt)
DE (1) DE60134749D1 (pt)
DK (1) DK1303490T3 (pt)
EC (1) ECSP034431A (pt)
EG (1) EG24968A (pt)
ES (1) ES2309075T3 (pt)
GT (1) GT200100137A (pt)
HK (1) HK1058198A1 (pt)
HR (1) HRP20030003B1 (pt)
HU (1) HU230316B1 (pt)
IL (2) IL153834A0 (pt)
JO (1) JO2372B1 (pt)
MA (1) MA26929A1 (pt)
ME (1) ME01311B (pt)
MX (1) MXPA03000366A (pt)
MY (1) MY154976A (pt)
NO (1) NO324700B1 (pt)
NZ (1) NZ523273A (pt)
PA (1) PA8522001A1 (pt)
PE (1) PE20020272A1 (pt)
PL (1) PL205207B1 (pt)
PT (1) PT1303490E (pt)
RS (1) RS50932B (pt)
RU (1) RU2266284C2 (pt)
SI (1) SI1303490T1 (pt)
UY (1) UY26839A1 (pt)
WO (1) WO2002006236A1 (pt)
ZA (1) ZA200210207B (pt)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1103545E (pt) * 1999-11-29 2004-03-31 Hoffmann La Roche 2-(3,5-bis-trifluorometil-fenil)-n-metil-n-(6-morfolin-4-il-4-o-totil-piridin-3-il)-isobutiramida
ATE400556T1 (de) * 2000-07-14 2008-07-15 Hoffmann La Roche N-oxide als nk1-rezeptorantagonistenprodrugs von 4-phenylpyridinderivaten
TWI287003B (en) * 2000-07-24 2007-09-21 Hoffmann La Roche 4-phenyl-pyridine derivatives
EP1385577B1 (en) * 2001-04-23 2006-04-19 F. Hoffman-la Roche AG Use of nk-1 receptor antagonists against benign prostatic hyperplasia
DK1643998T3 (da) * 2003-07-03 2007-12-27 Hoffmann La Roche NK1/NK3-antagonister til behandling af skizofreni
WO2006002860A1 (en) 2004-07-06 2006-01-12 F. Hoffmann-La Roche Ag Process for preparing carboxamide pyridine derivatives used as intermediates in the synthesis of nk-1 receptor antagonists
US20060030600A1 (en) * 2004-08-06 2006-02-09 Patrick Schnider Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia
WO2006089674A2 (en) 2005-02-25 2006-08-31 F.Hoffmann-La Roche Ag Tablets with improved drug substance dispersibility
DE602006005624D1 (de) * 2005-03-23 2009-04-23 Hoffmann La Roche Metaboliten für nk-i-antagonisten zur emesis
JP2008280248A (ja) * 2005-11-02 2008-11-20 Eisai R & D Management Co Ltd アルツハイマー型痴呆症治療薬塩酸ドネペジルのプロドラッグ
CN101641099A (zh) 2007-01-24 2010-02-03 葛兰素集团有限公司 包含3,5-二氨基-6-(2,3-二氯苯基)-1,2,4-三嗪或r(-)-2,4-二氨基-5-(2,3-二氯苯基)-6-氟甲基嘧啶和nk1的药物组合物
GB0808747D0 (en) 2008-05-14 2008-06-18 Glaxo Wellcome Mfg Pte Ltd Novel compounds
US8966414B2 (en) 2009-05-29 2015-02-24 Cypress Semiconductor Corporation Implementing a circuit using an integrated circuit including parametric analog elements
US9858367B1 (en) * 2009-08-31 2018-01-02 Cypress Semiconductor Corporation Integrated circuit including parametric analog elements
EP2722045B1 (en) 2009-11-18 2016-07-06 Helsinn Healthcare SA Compositions for treating centrally mediated nausea and vomiting
EP2727590B1 (en) 2009-11-18 2015-10-21 Helsinn Healthcare SA Compositions for treating centrally mediated nausea and vomiting
DK2744497T3 (en) 2011-10-18 2016-08-01 Helsinn Healthcare Sa THERAPEUTIC COMBINATION OF netupitant AND palonosetron
US8426450B1 (en) 2011-11-29 2013-04-23 Helsinn Healthcare Sa Substituted 4-phenyl pyridines having anti-emetic effect
AP2014007805A0 (en) 2011-12-28 2014-07-31 Cytokinetics Inc The Regents Of The University Of California Substituted benzaldehyde compounds and methods fortheir use in increasing tissue oxygenation
ES2790358T3 (es) 2011-12-28 2020-10-27 Global Blood Therapeutics Inc Compuestos de heteroaril aldehído sustituido y métodos para su uso en el aumento de la oxigenación tisular
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
EA034922B1 (ru) 2013-03-15 2020-04-07 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
ES2890077T3 (es) 2013-03-15 2022-01-17 Global Blood Therapeutics Inc Compuestos y usos de los mismos para la modulación de la hemoglobina
US9802900B2 (en) 2013-03-15 2017-10-31 Global Blood Therapeutics, Inc. Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin
US9604999B2 (en) 2013-03-15 2017-03-28 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10100043B2 (en) 2013-03-15 2018-10-16 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
ES2864707T3 (es) 2013-03-15 2021-10-14 Global Blood Therapeutics Inc Compuestos y usos de los mismos para la modulación de la hemoglobina
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
JP5806420B1 (ja) 2013-11-08 2015-11-10 キッセイ薬品工業株式会社 カルボキシメチルピペリジン誘導体
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
US10350098B2 (en) * 2013-12-20 2019-07-16 Volcano Corporation Devices and methods for controlled endoluminal filter deployment
BR112015032160B1 (pt) 2014-02-07 2021-11-30 Global Blood Therapeutics, Inc Ansolvato cristalino de composto, composição e composição farmacêutica
TWI649307B (zh) 2014-05-07 2019-02-01 日商橘生藥品工業股份有限公司 Cyclohexylpyridine derivative
CN106588899B (zh) * 2015-10-15 2019-11-15 江苏恒瑞医药股份有限公司 吡啶基取代的6-氧杂螺[4.5]癸烷类衍生物、其制备方法及其在医药上的应用
TW201731509A (zh) 2015-12-04 2017-09-16 全球血液治療公司 針對２-羥基-６-（（２-（１-異丙基-１ｈ-吡唑-５-基）吡啶-３-基）甲氧基）-苯甲醛之劑量方案
TWI752307B (zh) 2016-05-12 2022-01-11 美商全球血液治療公司 新穎化合物及製造化合物之方法
TWI778983B (zh) 2016-10-12 2022-10-01 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
JP7271437B2 (ja) 2017-04-10 2023-05-11 チェイス セラピューティクス コーポレイション Ｎｋ１拮抗薬組み合わせおよびシヌクレイノパチーを治療する方法
US11266633B2 (en) 2017-06-30 2022-03-08 Chase Therapeutics Corporation NK-1 antagonist compositions and methods for use in treating depression
ES2966707T3 (es) 2018-10-01 2024-04-23 Global Blood Therapeutics Inc Moduladores de la hemoglobina para el tratamiento de la drepanocitosis

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56106286A (en) 1980-01-28 1981-08-24 Nippon Musical Instruments Mfg Electronic musical instrument
EP0103545A3 (en) 1982-09-13 1984-10-03 Arc Technologies Systems, Ltd. Electrode for arc furnaces
IL111960A (en) 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
NZ277839A (en) 1993-12-29 1998-01-26 Merck Sharp & Dohme Substituted morpholine derivatives, preparation and pharmaceutical compositions thereof
TW385308B (en) 1994-03-04 2000-03-21 Merck & Co Inc Prodrugs of morpholine tachykinin receptor antagonists
DE19627431A1 (de) * 1996-07-08 1998-01-15 Bayer Ag Heterocyclisch kondensierte Pyridine
AR008789A1 (es) * 1996-07-31 2000-02-23 Bayer Corp Piridinas y bifenilos substituidos
US5972938A (en) 1997-12-01 1999-10-26 Merck & Co., Inc. Method for treating or preventing psychoimmunological disorders
NZ513322A (en) * 1999-02-24 2004-07-30 F Phenyl- and pyridinyl derivatives
DE60014216T2 (de) 1999-02-24 2006-03-02 F. Hoffmann-La Roche Ag 4-Phenylpyridinderivate und deren Verwendung als NK-1 Rezeptorantagonisten
PT1103545E (pt) * 1999-11-29 2004-03-31 Hoffmann La Roche 2-(3,5-bis-trifluorometil-fenil)-n-metil-n-(6-morfolin-4-il-4-o-totil-piridin-3-il)-isobutiramida
ATE400556T1 (de) * 2000-07-14 2008-07-15 Hoffmann La Roche N-oxide als nk1-rezeptorantagonistenprodrugs von 4-phenylpyridinderivaten
US20030083345A1 (en) * 2001-07-10 2003-05-01 Torsten Hoffmann Method of treatment and/or prevention of brain, spinal or nerve injury

Also Published As

Publication number Publication date
IL153834A0 (en) 2003-07-31
SI1303490T1 (sl) 2008-10-31
HK1058198A1 (en) 2004-05-07
US6593472B2 (en) 2003-07-15
CZ303639B6 (cs) 2013-01-23
NO324700B1 (no) 2007-12-03
ATE400556T1 (de) 2008-07-15
GT200100137A (es) 2002-05-16
CN1178917C (zh) 2004-12-08
HU230316B1 (hu) 2016-01-28
RS50932B (sr) 2010-08-31
JO2372B1 (en) 2006-12-12
HUP0301311A2 (hu) 2003-08-28
ME01311B (me) 2013-12-20
RU2266284C2 (ru) 2005-12-20
NO20030154L (no) 2003-01-13
AU7061901A (en) 2002-01-30
KR100501608B1 (ko) 2005-07-18
PE20020272A1 (es) 2002-04-16
US20040014793A1 (en) 2004-01-22
NZ523273A (en) 2004-08-27
US20020045642A1 (en) 2002-04-18
CN1441782A (zh) 2003-09-10
DE60134749D1 (de) 2008-08-21
MY154976A (en) 2015-08-28
HRP20030003B1 (en) 2011-01-31
JP3950044B2 (ja) 2007-07-25
US6747026B2 (en) 2004-06-08
US6897226B2 (en) 2005-05-24
CA2415890C (en) 2009-04-07
KR20030015387A (ko) 2003-02-20
YU603A (sh) 2006-01-16
HRP20030003A2 (en) 2003-02-28
PT1303490E (pt) 2008-09-04
DK1303490T3 (da) 2008-08-25
JP2004504301A (ja) 2004-02-12
EP1303490B1 (en) 2008-07-09
ECSP034431A (es) 2003-03-10
CY1108557T1 (el) 2014-04-09
BR0112475B1 (pt) 2013-10-15
EG24968A (en) 2011-03-14
US20040048901A1 (en) 2004-03-11
WO2002006236A1 (en) 2002-01-24
IL153834A (en) 2008-11-03
BRPI0112475B8 (pt) 2021-05-25
US20030149039A1 (en) 2003-08-07
ES2309075T3 (es) 2008-12-16
US6806370B2 (en) 2004-10-19
PL205207B1 (pl) 2010-03-31
PA8522001A1 (es) 2002-04-25
PL365684A1 (en) 2005-01-10
MA26929A1 (fr) 2004-12-20
AR029717A1 (es) 2003-07-10
EP1303490A1 (en) 2003-04-23
UY26839A1 (es) 2002-01-31
CA2415890A1 (en) 2002-01-24
MXPA03000366A (es) 2003-05-27
NO20030154D0 (no) 2003-01-13
ZA200210207B (en) 2004-03-17

Similar Documents

Publication Publication Date Title
BR0112475A (pt) N-óxidos como pró-drogas antagonistas de receptor de nk1 de derivados 4-fenil-piridina
YU8703A (sh) Derivati 4-fenil-piridina kao antagonisti receptora neurokinina-1
AR029821A1 (es) Decahidro-isoquinolinas, un proceso para su preparacion, composiciones farmaceuticas que las comprenden y el uso de las mismas para la fabricacion de un medicamento
SE0104334D0 (sv) Therapeutic agents
BR0111538A (pt) Derivados de 1,3,8-triaza-espiro 4,5!decan-4-ona como antogonistas de receptor de neurocinina
ES2171109A1 (es) Derivados de 4-fenil-piridina.
BRPI0518068A (pt) composto ou um éster ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica, inibidor seletivo de aurora a, agente anti-tumor, e, preparação combinada
MXPA03001518A (es) Composicion y metodo para inhibir la agregacion plaquetaria.
BRPI0518615A2 (pt) derivados de malonamida
WO2008101935A3 (fr) Nouveaux composés dérivés d'indole et compositions pharmaceutiques les contenant
NO20052074L (no) Substituerte benzoksazinoner og anvendelser derav.
WO2007039781A3 (en) 1,2,4-oxadioi.e derivatives with activity at the metabotropic clutamate receptors
BRPI0513084A (pt) antagonistas duplos de nk1/nk3 contra esquizofrenia
MY162998A (en) Ethynyl derivatives
NO20025640D0 (no) Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister
EA200300071A1 (ru) Терапевтический препарат для лечения невроза страха (тревоги) или депрессии и производные пиперазина
BR9814055A (pt) Composto, composição farmacêutica, processo para o tratamento de uma doença alérgica, uso do composto, e, processos para preparar e para produzir um composto
AR007108A1 (es) Agentes antitumorales y antivirales alquilantes, procedimiento para su preparacion, utilizacion de los mismos para la fabricacion de un medicamento y composicion farmaceutica que contiene a dichos agentes.
BR0011127A (pt) Derivados de 4-fenil-pirimidina
MXPA04003935A (es) Derivados de piridina como bloqueadores del subtipo de receptores n-metil-d-aspartato.
BR0115480A (pt) Derivados de pirimidina
NO20023041L (no) Fremgangsmåte for fremstilling av pyrazolopyridazinderivater
BR112012026458A2 (pt) derivados de pirazolopiridina
NZ519126A (en) Novel IL-8 receptor antagonists
PL378343A1 (pl) Pochodne benzoksazolu i ich zastosowanie jako ligandów receptora adenozyny

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DA INT.CL: C07D 213/76, C07D 213/82, C07D 401/04, A61K 31/44, A61P 25/22, A61P 25/24

Ipc: C07D 213/82 (2011.01), C07D 213/75 (2011.01), C07D

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 15/10/2013, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 09/07/2001 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 09/07/2021